SW-100
Based on 5 publication(s) in Google Scholar
SW-100, a selective histone deacetylase 6 (HDAC6) inhibitor with an IC50 of 2.3 nM, shows at least 1000-fold selectivity for HDAC6 relative to all other HDAC isozymes. SW-100 displays a significantly improved ability to cross the blood-brain-barrier.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.93%
- CAS. Nr.: 2126744-35-0
- Formel: C17H17ClN2O2
- Molecular Weight:316.78
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Targeted Diversity Library
HY-L099
-
Anti-Liver Cancer Compound Library
HY-L101
-
Osteogenesis Compound Library
HY-L131
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Efficiency Gene Editing Compound Library
HY-L244
-
Lactylation Compound Library
HY-L249
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Aging Compound Library
HY-L034
Publications Citing Use of MedChemExpress (MCE) SW-100
More
Biologische Aktivität
|
HDAC1 5.23 μM (IC50) |
HDAC2 32.8 μM (IC50) |
HDAC3 29.5 μM (IC50) |
HDAC4 10.9 μM (IC50) |
HDAC5 4.07 μM (IC50) |
HDAC6 2.3 nM (IC50) |
HDAC7 4.55 μM (IC50) |
HDAC8 3.72 μM (IC50) |
HDAC9 3.46 μM (IC50) |
HDAC10 26.2 μM (IC50) |
HDAC11 5.72 μM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
0.1 μM
Compound: SW-100
|
Inhibition of HDAC6 CD2 (unknown origin) expressed in HEK293 cells cotransfected with nano-luciferase incubated for 2 hrs followed by NanoBRET NanoGlo Substrate addition by NanoBRET assay
Inhibition of HDAC6 CD2 (unknown origin) expressed in HEK293 cells cotransfected with nano-luciferase incubated for 2 hrs followed by NanoBRET NanoGlo Substrate addition by NanoBRET assay
|
[PMID: 31414801] |
| Sf9 | IC50 |
2.3 nM
Compound: SW-100
|
Inhibition of recombinant N-terminal GST-tagged human HDAC6 (1 to 1215 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mins followed by s
Inhibition of recombinant N-terminal GST-tagged human HDAC6 (1 to 1215 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mins followed by s
|
[PMID: 31414801] |
| Sf9 | IC50 |
3.7 μM
Compound: 19
|
Inhibition of full length human recombinant HDAC8 (379 to 382 residues) expressed in baculovirus infected Sf9 insect cells using (RHK(Ac)K(Ac)AMC) as a fluorogenic susbstrate preincubated for 10 mins followed by substrate addition and measured after 1 hr
Inhibition of full length human recombinant HDAC8 (379 to 382 residues) expressed in baculovirus infected Sf9 insect cells using (RHK(Ac)K(Ac)AMC) as a fluorogenic susbstrate preincubated for 10 mins followed by substrate addition and measured after 1 hr
|
[PMID: 37399711] |
| Sf9 | IC50 |
5230 nM
Compound: SW-100
|
Inhibition of recombinant full length C-terminal His/FLAG tagged human HDAC1 (1 to 482 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mi
Inhibition of recombinant full length C-terminal His/FLAG tagged human HDAC1 (1 to 482 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mi
|
[PMID: 31414801] |
SW-100 (0.01-10 µM; 48 hours) shows obvious increase in the acetylated α-tubulin levels in a dose-dependent manner[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK293 cells
-
Concentration:0.01, 0.1, 1, 10 µM
-
Incubation Time:48 hours
-
Result:Showed obvious increase in the acetylated α-tubulin levels in a dose-dependent manner.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:8-10 weeks old C57BL/6 mice (Fmr1-/- mice)[1]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection; twice a day for two days
-
Result:Ameliorated several memory and learning impairments including novel object recognition, temporal ordering, and coordinate and categorical spatial processing in Fmr1-/- mice。
Chemical Information
-
CAS. Nr. 2126744-35-0
-
Appearance Solid
-
Molecular Weight 316.78
-
Formel C17H17ClN2O2
-
Color Light yellow to yellow
-
SMILES
O=C(NO)C1=CC=C(CN2CCCC3=C2C=CC(Cl)=C3)C=C1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Neural deficits in a mouse model of PACS1 syndrome are corrected with PACS1- or HDAC6-targeting therapy. [Abstract]2023 Oct 17;14(1):6547. PMID: 37848409 -
-
-
Res Sq
2023 Jan 27:rs.3.rs-2440581. PMID: 36747781 -
Lösungsmittel & Löslichkeit
DMSO : ≥ 125 mg/mL (394.60 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (6.57 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.1568 mL | 15.7838 mL | 31.5676 mL | 78.9191 mL |
| 5 mM | 0.6314 mL | 3.1568 mL | 6.3135 mL | 15.7838 mL | |
| 10 mM | 0.3157 mL | 1.5784 mL | 3.1568 mL | 7.8919 mL | |
| 15 mM | 0.2105 mL | 1.0523 mL | 2.1045 mL | 5.2613 mL | |
| 20 mM | 0.1578 mL | 0.7892 mL | 1.5784 mL | 3.9460 mL | |
| 25 mM | 0.1263 mL | 0.6314 mL | 1.2627 mL | 3.1568 mL | |
| 30 mM | 0.1052 mL | 0.5261 mL | 1.0523 mL | 2.6306 mL | |
| 40 mM | 0.0789 mL | 0.3946 mL | 0.7892 mL | 1.9730 mL | |
| 50 mM | 0.0631 mL | 0.3157 mL | 0.6314 mL | 1.5784 mL | |
| 60 mM | 0.0526 mL | 0.2631 mL | 0.5261 mL | 1.3153 mL | |
| 80 mM | 0.0395 mL | 0.1973 mL | 0.3946 mL | 0.9865 mL | |
| 100 mM | 0.0316 mL | 0.1578 mL | 0.3157 mL | 0.7892 mL |
SW-100 Related Classifications
HY-115475 Related Classifications
Powered by Bioz